| Code | CSB-RA023981MB5HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to BGB-A445, designed to target TNFRSF4 (tumor necrosis factor receptor superfamily member 4), also known as OX40 or CD134. TNFRSF4 is a costimulatory receptor expressed on activated T cells that plays a crucial role in regulating immune responses by enhancing T cell proliferation, survival, and effector function. Upon binding to its ligand OX40L, TNFRSF4 promotes sustained T cell activation and memory formation, making it a critical checkpoint in adaptive immunity. Dysregulation of TNFRSF4 signaling has been implicated in autoimmune diseases, inflammatory conditions, and cancer, where it represents a promising immunotherapeutic target for modulating antitumor immunity.
BGB-A445 is an investigational agonistic antibody that activates TNFRSF4 signaling to enhance T cell-mediated immune responses against tumors. This biosimilar antibody serves as a valuable research tool for investigating TNFRSF4 biology, exploring immune checkpoint modulation mechanisms, and evaluating combination immunotherapy strategies in preclinical cancer models and immune system studies.
There are currently no reviews for this product.